Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 3,500 Shares of Company Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Malik sold 3,500 shares of the stock in a transaction dated Tuesday, October 20th. The shares were sold at an average price of $64.01, for a total transaction of $224,035.00. Following the completion of the sale, the executive vice president owned 153,902 shares of the company’s stock, valued at approximately $9,851,267.02. The trade was a 2.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, October 6th, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $61.38, for a total value of $214,830.00.
• On Tuesday, September 22nd, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $68.29, for a total value of $239,015.00.
• On Tuesday, September 8th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $75.46, for a total value of $264,110.00.
• On Tuesday, August 18th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $75.82, for a total value of $265,370.00.

Cytokinetics Trading Up 2.1%

Shares of CYTK stock opened at $63.95 on Wednesday. The stock has a 50 day moving average of $69.63 and a two-hundred day moving average of $73.23. Cytokinetics, Incorporated has a 12 month low of $54.30 and a 12 month high of $88.31. The company has a market capitalization of $7.96 billion, a P/E ratio of -8.86 and a beta of 0.41.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to analyst estimates of $17.59 million. Cytokinetics’s revenue for the quarter was down 57.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.12) EPS. Sell-side analysts predict that Cytokinetics, Incorporated will post -5.98 earnings per share for the current fiscal year.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Health Canada approved MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III). The approval expands Cytokinetics’ international commercial opportunity and reinforces confidence in the drug’s regulatory and clinical profile. Health Canada approval announcement
• Positive Sentiment: Coverage highlighted growing MYQORZO prescriptions, international launches and encouraging clinical data, suggesting the product could become an increasingly important growth driver for Cytokinetics. MYQORZO growth analysis
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating with a $140 price target, implying substantial upside from recent trading levels and providing a bullish counterpoint to more cautious views. HC Wainwright rating report
• Neutral Sentiment: Cytokinetics granted options covering 60,465 shares and 40,084 restricted stock units to 29 recently hired employees as inducements. The grants support recruitment but may create modest future share dilution. Inducement grants announcement
• Negative Sentiment: BofA Securities lowered its price target to $81 from $85 while maintaining a Neutral rating, signaling less near-term conviction despite the target remaining above the recent share price. BofA price-target update
• Negative Sentiment: Wall Street Zen downgraded CYTK to Sell, adding to investor concerns about valuation, execution and the company’s continuing losses. Wall Street Zen rating downgrade
• Negative Sentiment: Executive Vice President Fady Malik sold 3,500 shares worth approximately $224,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but still represents a modest insider-selling overhang. SEC insider transaction filing

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CYTK. Needham & Company LLC lifted their price target on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. UBS Group restated a “buy” rating and issued a $104.00 price objective on shares of Cytokinetics in a research note on Wednesday, October 14th. Barclays increased their price objective on shares of Cytokinetics from $95.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $140.00 price objective on shares of Cytokinetics in a report on Monday. Finally, Citizens Jmp raised their price objective on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $105.44.

Institutional Investors Weigh In On Cytokinetics

Large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC acquired a new position in shares of Cytokinetics in the 2nd quarter worth approximately $36,000. Physician Wealth Advisors Inc. lifted its position in shares of Cytokinetics by 810.2% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 397 shares during the period. V Square Quantitative Management LLC boosted its stake in Cytokinetics by 71.5% in the 3rd quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 191 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in Cytokinetics by 842.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 641 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 573 shares in the last quarter. Finally, Western Wealth Management LLC acquired a new stake in Cytokinetics in the 1st quarter valued at $53,000.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.